川宁生物(301301) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥1,296,949,550.16, a decrease of 14.85% compared to ¥1,523,218,164.00 in the same period last year[7] - Net profit attributable to shareholders was ¥288,218,532.72, down 18.26% from ¥352,614,874.42 year-on-year[7] - Basic earnings per share were ¥0.13, reflecting an 18.75% decline from ¥0.16 in the same quarter last year[7] - Net profit for the current period was ¥288,206,596.52, down 18.3% from ¥352,626,111.92 in the previous period[27] Cash Flow - The cash flow from operating activities decreased significantly by 56.91%, amounting to ¥116,584,540.52 compared to ¥270,569,372.13 in the previous year[15] - Operating cash inflow for the current period was $648,163,490.34, down 18.2% from $792,326,034.25 in the previous period[30] - Net cash flow from operating activities decreased to $116,584,540.52, a decline of 56.9% compared to $270,569,372.13 in the prior period[31] - Cash outflow from investment activities totaled $422,965,903.29, significantly higher than $80,063,954.60 in the previous period[31] - Net cash flow from investment activities was -$222,501,544.38, worsening from -$79,956,654.60 in the prior period[31] - Cash flow from financing activities resulted in a net outflow of -$28,751,355.04, compared to -$66,575,155.57 in the previous period[31] - The ending balance of cash and cash equivalents was $952,641,363.26, an increase from $883,122,418.32 in the previous period[32] Assets and Liabilities - Total assets increased by 1.70% to ¥10,732,543,256.83 from ¥10,553,579,961.17 at the end of the previous year[7] - Total liabilities decreased to ¥2,525,346,199.76 from ¥2,637,164,117.24, a reduction of about 4.2%[24] - Non-current liabilities decreased to ¥553,278,437.67 from ¥689,629,227.58, a drop of about 19.7%[24] - The total non-current assets decreased to CNY 6,316,164,332.27 from CNY 6,409,356,087.63, a decline of approximately 1.5%[22] Equity - The total equity attributable to shareholders increased by 3.68% to ¥8,188,380,183.44 from ¥7,897,587,034.11 at the end of the previous year[7] - The company's retained earnings increased to ¥2,349,151,220.87 from ¥2,060,932,688.15, an increase of approximately 14.0%[24] Research and Development - Research and development expenses surged by 140.34% to ¥40,094,047.08, up from ¥16,682,182.70 year-on-year, indicating a strong focus on innovation[13] - The company is focusing on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[19] Investments - The company reported a significant increase in long-term equity investments by 139.78%, reaching ¥37,895,227.74, attributed to additional capital injections into joint ventures[12] - Long-term equity investments rose to CNY 37,895,227.74 from CNY 15,804,416.14, showing a significant increase of about 139.5%[22] Operational Costs - Total operating costs decreased to ¥947,594,552.57 from ¥1,098,639,822.39, a decline of approximately 13.7%[26] - The company experienced a 106.68% rise in selling expenses, totaling ¥7,951,719.02, primarily due to increased promotional and hospitality costs[13] Miscellaneous - The company has developed new data resources, with development expenditures recorded at CNY 1,000,000.00, which was not present in the previous period[22] - The company has not disclosed any significant mergers or acquisitions during this reporting period[19] - The company did not conduct an audit for the first quarter report[33]